Tag: TCT 2017
TCT 2017: The HREVS study provides supportive evidence for the hybrid revascularisation approach
The HREVS (Hybrid cor...
TCT 2017: Advances in device technology needed to improve outcomes with Absorb
Data from the ABSORB ...
TCT 2017: TMVI in mitral ring is a reasonable alternative for high-risk patients
Data from the MITRAL ...
TCT 2017: Study challenges recommendations on the management of cardiogenic shock
Advice on percutaneou...
TCT 2017: No advantage with extending dual antiplatelet therapy beyond six months in STEMI patients
The primary results f...
TCT 2017: Fantom bioresorbable scaffold continues to show positive outcomes at two years
The Fantom bioresorba...
TCT 2017: Two studies support feasibility of transcatheter mitral valve implantation
Early experiences wit...
TCT 2017: TAVI “should be the preferred strategy” for patients at intermediate-risk
David Cohen (Saint Lu...
TCT 2017: New data for CoreValve Evolut further support its use in intermediate-risk patients
New clinical research, ...
TCT 2017: AI-driven cardiac ultrasound company to give two presentations
Bay Labs, a medical techn...
Cobra PzF nano-coated stent now being studied with 14-day DAPT in patients at high risk of bleeding
The US FDA has approved t...
TCT 2017: Elixir Medical to reveal “a game-changing metallic drug-eluting stent platform”
Elixir Medical has reveal...
